Alirocumab, Praluent: Clinical studies: An overwiev

Abstract

Alirocumab, Praluent represents the new lipid lowerin drug from the group of PCSK9 inhibitors. The artickle provides an overwiev of clinical studies up to date

Keywords

• Alirocumab
• Praluent
• lipid lowering drugs
• PCSK9-inhibitors
• lipid lowering